250 related articles for article (PubMed ID: 20573390)
1. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
[TBL] [Abstract][Full Text] [Related]
4. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
5. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
6. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma.
Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ
J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252
[TBL] [Abstract][Full Text] [Related]
7. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
8. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
[TBL] [Abstract][Full Text] [Related]
9. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
11. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
Nisman B; Appelbaum L; Yutkin V; Nechushtan H; Hubert A; Uziely B; Pode D; Peretz T
Anticancer Res; 2016 Apr; 36(4):1791-7. PubMed ID: 27069161
[TBL] [Abstract][Full Text] [Related]
12. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
Oremek GM; Eigenbrodt E; Rädle J; Zeuzem S; Seiffert UB
Anticancer Res; 1997; 17(4B):3031-3. PubMed ID: 9329593
[TBL] [Abstract][Full Text] [Related]
13. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening SA
Urol Res; 2003 Dec; 31(6):358-62. PubMed ID: 14513300
[TBL] [Abstract][Full Text] [Related]
14. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy.
Araki K; Igarashi T; Tobe T; Mizoguchi K; Suzuki H; Furuya Y; Ichikawa T; Nakatsu HO; Ito H
Urology; 2006 Dec; 68(6):1178-82. PubMed ID: 17141843
[TBL] [Abstract][Full Text] [Related]
15. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA
J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861
[TBL] [Abstract][Full Text] [Related]
16. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
[TBL] [Abstract][Full Text] [Related]
17. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
18. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
20. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors.
Gilbert SM; Whitson JM; Mansukhani M; Buttyan R; Benson MC; Olsson CA; Sawczuk IS; McKiernan JM
Urology; 2006 May; 67(5):942-5. PubMed ID: 16698354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
